Literature DB >> 1527046

The antiproliferative activity of arterial heparan sulfate resides in domains enriched with 2-O-sulfated uronic acid residues.

A Schmidt1, K Yoshida, E Buddecke.   

Abstract

Heparan sulfate isolated from bovine arterial tissue by a multistep purification procedure or from arterial tissue proteoheparan sulfate by beta-elimination exhibits antiproliferative activity toward arterial smooth muscle cells when added to subconfluent cell cultures in a concentration of 50-100 micrograms/ml medium. Enzymatic disintegration of heparan sulfate by heparitinases I and II and isolation of the resulting oligosaccharides indicate that the antiproliferative activity of the heparan sulfate molecule resides in a sulfate-rich octa/decasaccharide domain which is separated by longer sequences of sulfate-free or sulfate-poor N-acetylglucosamine containing disaccharide units. The octa/decasaccharide fraction has a 3-4-fold higher antiproliferative activity than the native heparan sulfate molecule and contains 45% of a disulfated disaccharide which consists of 2-O-sulfated uronic acid and N-sulfated glucosamine (UA(2S)-GlcNS and 12% of a trisulfated disaccharide (UA(2S)-GlcNS(6S). A sulfate-rich hexasaccharide fraction containing 14% of the disulfated disaccharide but 18% of the trisulfated disaccharide has negligible antiproliferative activity. The results indicate the presence of specific structural determinants in the arterial heparan sulfate molecule which may have the function of an endogenous inhibitor of arterial smooth muscle cell growth.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1527046

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Cholesterol-dependent changes of glycosaminoglycan pattern in human aorta.

Authors:  R Kruse; M Merten; K Yoshida; A Schmidt; W Völker; E Buddecke
Journal:  Basic Res Cardiol       Date:  1996 Sep-Oct       Impact factor: 17.165

2.  Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound.

Authors:  H Q Miao; D M Ornitz; E Aingorn; S A Ben-Sasson; I Vlodavsky
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

3.  Differential binding of platelet-derived growth factor isoforms to glycosaminoglycans.

Authors:  Raquel García-Olivas; Johan Hoebeke; Susanna Castel; Manuel Reina; Gunnar Fager; Florentina Lustig; Senén Vilaró
Journal:  Histochem Cell Biol       Date:  2003-10-14       Impact factor: 4.304

4.  Inhibition of anastomotic intimal hyperplasia by a synthetic nonsulphated heparin-mimicking compound.

Authors:  Yaron Shargal; Nicola Viola; Arnon Nagler; Gideon Merin; Annete Schmidt; Erick Buddecke; Shmuel A Ben-Sasson; Israel Vlodavsky
Journal:  Exp Clin Cardiol       Date:  2002

5.  Evaluation of a novel thermosensitive heparin-poloxamer hydrogel for improving vascular anastomosis quality and safety in a rabbit model.

Authors:  Ying-Zheng Zhao; Hai-Feng Lv; Cui-Tao Lu; Li-Juan Chen; Min Lin; Ming Zhang; Xi Jiang; Xiao-Tong Shen; Rong-Rong Jin; Jun Cai; Xin-Qiao Tian; Ho Lun Wong
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

6.  Acetylation may strengthen the antitumor activity of low molecular heparin.

Authors:  Ying Liang; Guixin Duan; Yuanyuan Wang; Guowen Wang; Ansheng Wang; Kangwu Wang
Journal:  Transl Cancer Res       Date:  2021-01       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.